Abstract
Background and Aims: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are useful agents for the treatment of type 2 diabetes, and have also demonstrated cardiovascular benefits beyond glycemic control. Recently, the SGLT2i dapagliflozin was approved as an adjunct to insulin in adults with type 1 diabetes (T1DM).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
